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ABSTRACT 
P2X7 purinoceptor promotes survival or cytotoxicity depending on extracellular ATP (eATP) 
stimulus intensity controlling its ion channel or P2X7-dependent large pore (LP) functions. 
Mechanisms governing this operational divergence and functional idiosyncrasy are ill-
understood. We have discovered a feedback loop where sustained activation of P2X7 triggers 
release of active MMP-2, which halts i o n  channel and LP responses via the MMP-2-dependent 
receptor cleavage. This mechanism operates in cells as diverse as macrophages, dystrophic 
myoblasts, P2X7-transfected HEK293 and human tumor cells. Given that serum-born MMP-2 
activity also blocked receptor functions, P2X7 responses in vivo may decrease in organs with 
permeable capillaries. Therefore, this mechanism represents an important fine-tuning of P2X7  
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functions, reliant on both cell-autonomous and extraneous factors. Indeed, it allowed evasion from 
the ATP-induced cytotoxicity in macrophages and human cancer cells with high P2X7 expression 
levels. Finally, we demonstrate that P2X7 ablation eliminated gelatinase activity in inflamed 
dystrophic muscles in vivo. Thus, P2X7 antagonists could be used as an alternative to highly toxic 
MMP inhibitors in treatments of inflammatory diseases and cancers. 
 
 
 
 
 
INTRODUCTION 
High concentration of eATP, which normally occurs in damaged tissues only, is one of the 
danger-associated molecular patterns (DAMPs). High (mM) eATP concentrations signal through the 
P2X7 purinergic receptor. Unlike other P2Xs, it is fully activated by significantly higher eATP and 
triggers the ―danger‖ response in inflammatory cells (de Torre-Minguela et al., 2016). Therefore, 
P2X7 is a therapeutic target in inflammatory diseases (Bartlett et al., 2014). An interesting property 
of P2X7 is that this ATP-gated ion channel, under some conditions, can trigger non-specific 
passage of molecules of up to 900 Da. While the mechanism of this large pore (LP) opening is 
still disputed (Browne et al., 2013; Pippel et al., 2017), it is undoubtedly associated with cell death 
via a range of unique pathways (e.g. aponecrosis, autosis, etc.) and, as we recently discovered, 
with autophagy (Young et al., 2015). Further complexity of P2X7 response is illustrated by the 
findings that low-level eATP stimulation of this purinoceptor can result in tonic/trophic effects such as 
increased cellular glycolysis, proliferation, migration and invasion (Rigato et al., 2012; Amoroso et 
al., 2012; Xia et al., 2015). Studying purinergic abnormalities in Duchenne muscular dystrophy 
(Young et al., 2012; Sinadinos et al., 2015) we observed that myoblasts carrying a premature 
stop codon in the Dmd gene can display two markedly different modes of response to eATP: one 
extreme - autophagic cell death (Young et al., 2015) and the second, a cellular detachment 
response. Therefore, we have sought to elucidate the mechanism(s) governing this response 
diversity and allowing cells expressing high P2X7 levels to survive in the high eATP 
environment. We found the LP opening to be triggering the release of active matrix metalloproteinase 
2 (MMP-2). Interestingly, while P2X7 activation was previously linked to MMP-9 release (Gu and 
Wiley, 2006) and MMP-2 and MMP-9 are both the gelatinases (Visse and Nagase, 2003; Page-
McCaw et al., 2007), only the MMP-2 release is of functional consequences to the cell and the 
P2X7 receptor itself: We found P2X7-evoked MMP2 activity to regulate cell migration, invasion and 
remodeling of extracellular matrix and its receptors. We demonstrate, for the first time, P2X7-
dependent cleavage of β-dystroglycan, a dystrophin-associated ECM receptor, in both myoblasts 
and macrophages. Importantly, we found that active MMP-2 released following LP formation also 
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cleaves P2X7 receptors. Therefore, we identified a novel feedback loop mechanism in which high 
eATP triggers P2X7 LP formation that regulates active MMP-2 release, which, in turn, halts the 
receptor function. Importantly, this mechanism afforded an evasion path from LP-induced 
cytotoxicity in cancer cells harboring high P2X7 levels. 
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RESULTS 
 
Dystrophic myoblasts display increased MMP-2 activity, which is released upon P2X7 activation 
The quantitative phosphoproteomic analysis of ATP-treated mdx myobalsts (from the DMDmdx mouse 
model of Duchenne muscular dystrophy) revealed significant differences in the phosphorylation of 
the ERM proteins: Ezrin, Radixin and Moesin [Supplementary Figure S1A], with established roles in 
cell adhesion and migration (Yonemura et al., 1998; DesMarais et al., 2005; Li et al., 2007). 
Therefore, we performed cell migration and invasion assays and found that dystrophic cells 
treated with BzATP (300µM) became polarized in their direction of migration, whereas WT 
myoblasts moved more randomly [Supplementary Figure S1B]. Moreover, significantly increased 
migration and invasion rates through gelatin were observed for dystrophic myoblasts treated with 
300µM BzATP [Supplementary Figure S1C, left panel]. These responses were completely blocked by 
the addition of the P2X7 antagonist A438079 or extracellular Ca2+ chelator EDTA [Supplementary 
Figure S1C, right panel] Given this invasion through gelatin, where MMPs have been implicated as 
downstream mediators (Xia et al., 2015; Qiu et al., 2014), we investigated the MMP activity in these 
cells.  
P2X7-dependent MMP-9 release has been documented in peripheral blood mononuclear cells of 
mouse and human origin (Gu and Wiley, 2006). Surprisingly, in gel zymography (IGZ) (Vandooren 
et al., 2013) with gelatin immobilised in polyacrylamide gels revealed that dystrophic myoblasts 
display significantly elevated MMP-2 activity compared to WT myoblasts, while MMP-9 activity 
actually appeared reduced in dystrophic cell extracts (Figure 1A and Supplementary Figure S2). 
Where referred to throughout, ‗MMP-2 activity‘ is used to indicate the presence of the 
enzymatically active mature form of MMP-2. Indeed, Western blotting analysis of these cell 
extracts revealed that MMP-2 protein levels were significantly lower in mdx than WT myoblasts 
(Figure 1B) thus excluding any possibility of a non-specific activation of MMP-2 during IGZ. 
Furthermore, MMP-9 protein expression was comparable across all samples (Figure 1B). 
Therefore, further investigations were focused on MMP-2. IGZ using cell pellets and supernatants 
collected from ATP stimulated mdx cells showed MMP-2 activity in cell pellets to fall over a period 
of 60 min following P2X7 activation, which correlated with the increased MMP-2 activity in 
supernatants (Figure 1C, D). Whilst MMP-9 did show a reduced signal in the pellet at 15 min, this was 
the same for both mdx and WT cells (the latter not expressing P2X7) and therefore not a P2X7-
dependent response. BzATP (a more selective P2X7 agonist) evoked the same pattern of MMP-2 
release and the concentration range triggering this effect was consistent with the P2X7 receptor 
activation (Supplementary Figure S3). Immunoblotting using anti-MMP-2 antibody confirmed the 
release of MMP-2 protein from cells (Figure 1E, F) into supernatants (Figure 1G, H). Elevated 
MMP-2 activity in supernatants was later followed by some LDH release indicating a degree of cell 
deaths (Figure 1H).  Finally, MMP-2 activity changes were eliminated by the P2X7 large pore 
antagonist A438079 treatment (Figure 1I, J), further confirming this effect to be P2X7-specific. 
Downloaded from https://academic.oup.com/jmcb/article-abstract/doi/10.1093/jmcb/mjx030/4084680/Sustained-activation-of-P2X7-induces-MMP-2-evoked
by University of Portsmouth Library user
on 04 September 2017
  
 
MMP activity triggered by P2X7 pore formation leads to cleavage of β-dystroglycan and CD44 
We next considered potential MMP-2 targets; given that β-dystroglycan in muscle is a well-known 
ECM receptor involved in cell adhesion and motility (Thompson et al., 2008) and that it has been 
shown to be a target for MMPs in different tissues (Yamada et al., 2001; Sbardella et al., 2015; 
Michaluk et al., 2007) we analyzed this protein by Western blotting. In dystrophic but not wild type 
myoblasts the P2X7 activation, shown previously to cause MMP-2 release, resulted in β-dystroglycan 
cleavage (Figure 2A, B). This effect was P2X7-dependent as it was absent in mdx/P2X7-/- c e l l s  
(Xia et al., 2015) l a c k i n g  P 2 X 7  r e c e p t o r s  (see Figure 4C). The resulting disruption of the 
link between the ECM and the cell membrane dystroglycan may explain the cell detachment 
response and enhanced migration of dystrophic cells (Supplementary Figure S1). CD44 is 
another known MMP target (Chetty et al., 2012), which is also an interacting partner of the ERM 
proteins (Visse and Nagase, 2003). Moreover, CD44 cleavage products have been shown to bind 
to and augment activation of P2X7 receptors (Moura et al., 2015). We therefore hypothesized that a 
similar mechanism may operate in dystrophic cells. Interestingly, while we found that CD44 
cleavage did occur in mdx myoblasts (Figure 2C, D), it was not associated with the expected 
augmentation of P2X7 functions. In fact, we uncovered downregulation of P2X7 responses 
subsequent to MMP release. 
 
MMP-2 is a suppressor of P2X7 receptor functions 
In our previous work, we found P2X7-dependent pore formation and autophagic cell death to be 
completely absent in the presence of serum (>5%) in the medium (Young et al., 2015; Sinadinos 
et al., 2015). Given that the serum is a rich source of proteases including MMPs, cathepsins and 
trypsins (Thrailkill et al., 2005; Weitoft et al., 2015; Artigas et al., 1981), we investigated the 
possibility that the serum MMP-2 is a critical factor in mediating this P2X7 response inhibition. 
Indeed, P2X7-dependent MMP-2 release, measured by the decreasing activity in cell pellets, was 
only observed in serum-free media and completely blocked when myoblasts or macrophages 
were analyzed in high-serum (Figure 3A). P2X7 LP function measured by EtBr uptake was also inhibited 
by the increasing serum concentrations but only if the serum contained active MMP-2 (Figure 3B, C). 
Titration of MMP-2 inhibitor I (Millipore) showed that at 67µM it effectively blocked MMP-2 (Figure 3D) 
without affecting MMP-9 activity. Pre-incubation of cells with this compound resulted in 
significantly enhanced P2X7-evoked EtBr uptake (Figure 3E). Importantly, active MMP-2 
(recombinant protein or present in a serum) inhibited specific P2X7 calcium channel activity 
too (Figure 3F). In contrast, inhibitors of cathepsins and trypsins, having, no effect on MMP-2 
activity [Supplementary Figure S4A], were completely ineffective in altering P2X7 functions 
[Supplementary Figure S4B]. This confirmed the specific effect of MMP-2 on P2X7 (Figure 3G).   
 
P2X7-dependent MMP-2 release occurs in macrophages and P2X7-transfected HEK293 cells 
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Next, we studied whether this mechanism is universal. Given the known P2X7 role in 
macrophages, we examined P2X7-dependent MMP-2 release in the RAW264 mouse 
macrophages (Figure 4A, B), in primary mouse peritoneal macrophages (Figure 4C, D) but also in 
HEK293 cells transfected with mouse P2X7 (HEKP2X7, Figure 4H). Importantly, these HEKP2X7 
showed no MMP-9 activity thus confirming the response to be MMP-2 specific.  Macrophages 
displayed a more rapid release of MMP-2 in response to BzATP (Figure 4A), consistent with 
higher P2X7 receptor expression levels in these cells when compared to dystrophic myoblasts 
(Young et al., 2015).  This response was a g a i n  completely abolished in the presence of high 
serum (Figure 4A, B). Crucially, double negative primary macrophages isolated from mdx/P2X7-/- 
mice (Sinadinos et al., 2015) did not display intracellular MMP-2 activity or extracellular MMP-2 
release in response to BzATP treatment, confirming the response to be P2X7 dependent (Figure 
4C). Macrophages also displayed β-dystroglycan cleavage, which was completely absent in P2X7 
knockout-derived cells (KO, Figure 4E). Indeed, this response was more rapid than in myoblasts; 
macrophages displayed complete cleavage of the 43 kDa β-dystroglycan band within 30 min of 
BzATP stimulation, which may again reflect the increased level of P2X7 expression in these cells. 
Interestingly, transfection of HEK cells with P2X7 [Supplementary Figure S5] was bo th  
necessa ry  and  sufficient to confer P2X7-dependent MMP-2 release from these cells in 
response to BzATP (Figure 4H). 
 
P2X7 is a proteolytic target for MMP-2 
Given the MMP-2 release in response to P2X7 activation and that this lead to down regulation of 
receptor functions, we investigated the possibility that P2X7 itself could be a target for MMP-2 
cleavage. CleavPredict (Sandford Burnham) analysis revealed multiple putative cleavage sites for 
MMP-2 in mouse and human P2X7 sequences [Supplementary Figure S6A]. Therefore, we 
performed Western blotting with anti-P2X7 antibody in samples from BzATP-treated cells under 
conditions where MMP-2 is released. We found reduced levels of the 80 kDa P2X7 band 60 min 
after BzATP treatment (Figure 5A) and increasing amounts of a potential C-terminal cleavage 
product (~35 kDa) occurring after 30 min. This cleavage product was not present in samples pre-
incubated with MMP-2 Inhibitor I (Figure 5A, lower panel).  Significant cleavage was already 
observed 15 mins following P2X7 activation (Figure 5C). For a direct confirmation, protein 
lysates from mdx myoblasts, peritoneal macrophages and HEKP2X7 cells were incubated with 
activated or inactive recombinant mouse MMP-2 for 30 min at 37◦C. We observed a cleavage 
product of the same molecular weight as that seen in BzATP-treated cells, when active recMMP-2 
was used. This band was absent in samples treated with inactive recMMP-2 (Figure 5E). The size 
of this cleavage product (~35 kDa) corresponded with predicted cleavage sites at positions 277 and 
298 (Figure 5G). The first site is particularly well conserved across species [Supplementary Figure 
S6B]. Combination of data obtained using recMMP-2 and its blocker in cells and in protein extracts 
confirmed that P2X7 is a trigger for the release as well as the proteolytic target for MMP-2. 
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MMP-2 release blocks P2X7 pore formation and ATP-induced death in tumor cells 
P2X7 has been found up-regulated in tumors including as diverse types as breast (Ma, 2015), 
brain (Monif et al., 2014) and prostate (Qiu et al., 2014). Tumor cells were found to benefit from 
increased mitochondrial metabolic activity and growth caused by increased P2X7 expression (Di 
Virgilio et al., 2009). However, there is a question: How these cells avoid death associated with this 
high-level P2X7 expression and activation in high eATP environments? Discovery of the MMP-2-
dependent P2X7 cleavage prompted us to investigate whether tumor cells exploit this mechanism to 
evade the cell death. Firstly, we interrogated the Cancer Genome Atlas database and found that 
over-expression of P2X7 and MMP-2 in prostate cancer samples coincide [Supplementary Figure 
S7]. We then confirmed very high levels of P2X7 receptor expression in the human LNCaP prostate 
cancer cells (Figure 6A). However, EtBr uptake in these cells following 30 min stimulation with 
3mM ATP was not as strong as would be expected from such high P2X7 expression levels (Figure 
6B) and there was no cell rounding, detachment or blebbing (data not shown).  In contrast, a 
significant P2X7-dependent EtBr uptake was observed when MMP-2 activity was blocked (Figure 
6B). In gel zymography showed constitutively high levels of MMP-2 being released from LNCaPs into 
the supernatant, which was further elevated in the presence of P2X7 agonists (Figure 6C). This high 
extracellular MMP-2 activity coincided with constitutively high levels of the P2X7 cleavage product 
(Figure 6A), which could explain these surprisingly low P2X7 responses in cancer cells despite a 
high-level receptor expression. Finally, the eATP-evoked cell death of LNCaPs in the LP-buffer 
was found very low and completely attenuated in the presence of MMP-2-containing serum but 
enhanced four-fold by the MMP-2 inhibitor (Figure 6D).  
Therefore, this active MMP-2 release appears to be a universal protective mechanism, fine-tuning 
P2X7 receptor responses in various cell types, allowing stimulation sufficient for promoting growth 
and survival whilst minimizing pore formation and cell death. 
 
P2X7 inhibition ablates gelatinase activity in mdx skeletal muscle in vivo 
Upregulation of P2X7 receptor expression has been documented in a number of muscular 
dystrophies with an inflammatory component, including DMD and LGMD2b (Young et al., 2012; 
Sinadinos et al., 2015; Rawat et al., 2010; Gazzerro et al., 2015). Notably, we have recently 
demonstrated multifaceted beneficial effects of P2X7 ablation and pharmacological inhibition on 
DMD pathology (Sinadinos et al., 2015). Here we found that ablation of the P2X7 receptor in mdx 
mice also results in significant reductions in gelatinase activity in dystrophic skeletal muscles in 
vivo. Gelatinase activity in mdx muscles was found to be concentrated around populations of 
infiltrating inflammatory cells but, interestingly, also associated with nuclei of regenerating fibers 
(Figure 7A, upper right and inset panels). The significant reduction of this activity in muscles of 
mdx/P2X7-/- animals (Figure 7B) supports the finding of P2X7-dependent MMP-2 activity and 
highlights an important new pathological pathway that is ameliorated by P2X7 ablation (Sinadinos 
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et al., 2015). In contrast to this in situ activity, Western blotting showed no reduction in MMP-2 or 
MMP-9 protein levels in mdx/P2X7-/- compared to mdx muscles (Figure 7C). In fact, lower levels of 
MMP-2 were observed in mdx compared to WT lysates, indicating that dystrophic muscle retains the 
abnormal MMP-2 phenotype found in dystrophic myoblasts (Figure 1). 
 
 
DISCUSSION 
Enhanced migratory/invasive behavior following P2X7 activation led us to the identification of 
significantly elevated MMP-2 activity in dystrophic muscle cells, where P2X7 itself is upregulated. 
MMP-2 was released in a P2X7-dependent manner and effected the cleavage of β-dystroglycan 
and CD44 - well documented orchestrators of cellular attachment and migration. Surprisingly, 
MMP-2 release was found to coincide with the cessation of P2X7 functions.  We demonstrated 
this to be due to the proteolysis of P2X7 by MMP-2.  Based on these results, we propose that 
P2X7 signalling responses are modulated by a novel feedback loop involving MMP-2-evoked 
proteolytic processing, rendering the P2X7 non-functional. We demonstrated the universality of this 
mechanism by confirming it in macrophages and HEK293 cells expressing P2X7. We also 
demonstrated the clinical relevance of these findings by showing that P2X7 ablation abrogates 
gelatinase activity in dystrophic muscles in situ. Finally, we showed that MMP-2 inhibition triggers 
death of human cancer cells, which were otherwise unresponsive to eATP stimulation and thus 
the P2X7-dependent MMP-2 release represents a fine tuning mechanism for P2X7 receptor 
functions, imparting the ability to benefit from the P2X7 over-expression for growth and metabolism, 
whilst protecting against P2X7 large pore-induced cell death in the high eATP environment. 
 
We propose that P2X7 possesses its own autocrine signalling feedback through MMP-2. We 
showed that MMP-2 cleavage does not differentiate between pore and channel activity, as both are 
blocked (Figure 3E & 3F). However, only during the high level or chronic stimulation, the LP 
becomes activated and MMP-2 is released, hence MMP-2 activity affects the pore over the Ca2+ 
channel function. This provides an elegant system of enzymatic tuning, which can regulate P2X7 
signaling in every cell type. Cleavage predictions mapped the MMP-2 sites to residues R277 and 
298 (Figure 5G). The first region is particularly well conserved across the species [Supplementary 
Figure S6B] and indeed we found this mechanism operant in human and mouse cells. Moreover, 
this region has been reported to harbour the P2X7 gain of function mutation, R276A (Thompson et 
al., 2010). We therefore hypothesise that this gain of function is conferred through the ablation of 
this MMP-2 site, as confirmed by CleavPredict and further experiments are underway to ascertain 
whether cleaved domains of P2X7 retain any function. 
 
Overall, this work provides new insight into the molecular mechanisms of P2X7 function and 
regulation orchestrating the purinergic signalling (Figure 8). It is interesting to consider the 
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physiological implications of this mechanism, where P2X7 expressing cells would respond to high 
eATP differently: The same receptor density on the same cell may produce a significantly different 
effect in organs with discontinued capillaries (sinusoids) permitting serum proteins, including MMP-
2, to leave the bloodstream. Therefore, sinusoids in the liver, endocrine, lymphoid and 
hematopoietic organs (e.g. spleen and bone marrow) present P2X7 with a working environment 
entirely different to that in the CNS, sheltered behind the blood-brain barrier. Moreover, in 
pathological conditions disrupting integrity of blood vessels or BBB functions, P2X7 functions may 
change significantly. 
 
Moreover, P2X7 has established roles in cell migration and invasion, with notoriety in tumour 
metastasis, where MMPs have been implicated as downstream mediators of the eATP response 
(Xia et al., 2015; Qiu et al., 2014). We have shown inter-dependence of these responses and 
identified β-dystroglycan as a target. Dystroglycan is also a known component of focal adhesions 
in myoblasts (Kwan et al., 2004). Interestingly, we found P2X7-dependent MMP activity associated 
with central nuclei of regenerating myofibers, which raises questions about its function there; 
MMP-2 in cardiomyocyte nuclei might cleave PARP, a DNA-repair enzyme (Schwarz et al., 2012). 
However, although intracellular MMP-2 activity has been demonstrated, including in skeletal 
muscles (Hadler-Olsen et al., 2015), mechanisms governing the balance between intra- and 
extracellular MMP-2 remain elusive (Ali et al., 2012). 
 
In both skeletal muscles and muscle cells, we found significantly elevated MMP-2 activity, yet 
MMP-2 protein levels were downregulated compared to WT. Clearly, expression of MMPs cannot 
be used as an indicator of its activity as the latter is controlled in a complex manner involving the 
tissue inhibitors of metalloproteinases (TIMPs). However, the release of MMP-2 correlated with 
shifting its activity from intra to extracellular compartments, suggesting that it was due to changes 
in MMP-2 localisation and not because of its associated TIMPs. P2X7 expression is upregulated in 
several human cancers (Adinolfi et al., 2012) and P2X7 has been implicated in tumor growth-
promotion (Di Virgilio et al., 2009; Di Virgilio, 2015). Intriguingly, cancer cells appear to be able to 
reap the rewards of elevated P2X7 receptor expression without suffering the consequences of LP-
associated cell death. The molecular mechanisms behind this remarkable paradox were a mystery. 
Here we show for the first time that cancer cells are able to benefit from the P2X7 tonic stimulation 
without succumbing to P2X7 toxicity through MMP-2 release causing direct receptor cleavage. 
cBioportal (Cerami et al., 2012) analysis of P2X7 and MMP-2 expressions in the Cancer Genome 
Atlas (TCGA) showed upregulation of both mRNAs in all tumor types [Supplementary Figure S7A] 
with a strong correlation between expression levels in prostate cancers [Supplementary Figure 
S7B]. Indeed, we have confirmed this P2X7 cleavage in the human LNCaP prostate cancer cells. 
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In therapeutic terms, we have shown reduced gelatinase activity in areas of infiltrating 
macrophages in mdx/P2X7-/- muscles at the height of the pathology in these animals. Therefore, 
P2X7 antagonism shown to inhibit fiber damage, myogenic cell death and reduce inflammation 
(Sinadinos et al., 2015), also involves MMP inhibition. MMP-9 ablation in mdx mice has 
documented beneficial effects, with reduced levels of necrosis and neutrophil invasion but only at 
the acute disease phase (Shiba et al., 2015; Hindi et al., 2013). Interestingly, MMP-2 ablation has 
been shown to impair both angiogenesis and myofiber regeneration in mdx model (Miyazaki et al., 
2011). This data highlights the problem with global MMP inhibition. Our results suggest that P2X7 
receptor antagonists may offer a targeted alternative to the global MMP antagonism, preventing the 
serious side effects associated with such treatments (Cathcart et al., 2015). Receptors are more 
―druggable‖ and several P2X7 antagonists are already available (Bartlett et al., 2014); this 
approach might be applicable to a host of MMP-associated pathologies, including infectious diseases 
(sepsis), cancer, rheumatoid arthritis, atherosclerosis, inflammation, cardiomyopathy and, last but 
not least, muscular dystrophies. 
Given that both MMP-2 and MMP-9 gelatinases can be released following P2RX7 stimulation, it is 
remarkable that MMP-2 knockout exacerbated inflammatory arthritis while MMP-9 knockout 
reduced it (Itoh et al., 2002; Xue et al., 2014). Moreover, MMP-2 mutation causes a multicentric 
osteolysis and arthritis syndrome in humans (Martignetti et al., 2001). Our data provide molecular 
insight into this divergence as MMP-2 ablation would eliminate the natural ―off‖ switch for pro-
inflammatory P2X7. 
 
In conclusion, our results provide a novel mechanistic insight into the molecular signalling 
pathways associated with the elusive P2X7 large pore; the MMP-2 feedback loop we described 
here represents a first indication of how physiological niches can regulate P2X7 pore function 
through variations in serum concentration or MMP-2 uptake/release. The implications of this are 
significant for both immunology and pathology, given the important roles of both P2X7 and 
metalloproteinases in inflammatory and degenerative disorders (Cauwe et al., 2010). Finally, we 
postulate that P2X7 functions in vivo can vary significantly between the same cell type located in 
organs with different serum accessibility e.g. spleen and brain. This mechanism may also explain 
why, in tumors, high density of P2X7 in the presence of high eATP does not lead to P2X7- driven 
cell death. 
 
MATERIALS AND METHODS 
Animals 
C57BL10, DMD m d x  (mdx) and mdx/P2X7-/- (Sinadinos et al., 2015) 8 week old male mice were 
used in accordance with institutional Ethical Review Board and the Home Office (UK) Approvals.  
All mice were maintained under pathogen-free conditions and in a controlled environment (12hr 
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light/dark cycle, 19-23◦C ambient temperature, 45-65% humidity). Mice were killed by CO2 
inhalation and cells and muscles dissected and used for protein extraction, or frozen in isopentane 
pre-chilled in liquid nitrogen for cryosectioning. 
Antibodies and reagents 
The following antibodies were used at 1:1000: anti-P2X7 (177003, Synaptic Systems), anti-MMP-2 
(TP220, Amsbio), anti-MMP-9 (TP221 Amsbio), anti-actin (A2066, Sigma), anti-GAPDH (G9545, 
Sigma), anti-HCAM/CD44, (Santa Cruz, sc-18849). Anti-F4/80 (Abcam, ab6640) was used at 1:200 
and anti- β-dystroglycan (DSHB, MANDAG2(7D11)) was used at 1:50 dilution. Other reagents 
used: P2X7 antagonist A438079 (10M, Tocris Bioscience), MMP-2 inhibitor I (Millipore). All other 
chemicals were purchased from Sigma. Agonists were used at concentrations of 3mM (ATP) and 
0.5 mM (BzATP), unless stated otherwise.  
Cell culture 
Wild-type and dystrophic myoblasts (with a premature stop codon in exon 23 of the Dmd gene) 
(Browne et al., 2013) were cultured as primary cells in KnockOut DMEM (Invitrogen) 
supplemented with 10% v/v KSR (Knockout Serum Replacement, Invitrogen), 5% v/v DHS 
(Donor Horse Serum, Sera Labs) and 2mM L-glutamine. Peritoneal macrophages isolated by 
lavage with 5ml ice cold PBS-containing 1% FBS (Sigma) were maintained in 10% v/v FBS and 
2mM L-glutamine. Raw264.7 mouse macrophages (ATCC) were cultured as per peritoneal 
macrophages. LNCaP cells (ATCC; CRL-1740™) were maintained in 50:50 DMEM F12 HAMS, 
RPMI 1640, supplemented with 10% v/v FBS (Sigma) and 2mM L-glutamine. Following cell 
culture cells were washed to remove all traces of serum and analyzed in an appropriate serum-
free assay buffer. 
Zymography 
For IGZ, all experiments were conducted in serum-free physiological saline buffer (145mM NaCl, 
5mM KCl, 1mM MgCl2 and 10mM Na-HEPES). Subsequently, cells were scraped in lysis buffer 
containing 50mM Tris base, 0.5% v/v Triton, pH 7.4. 30-40g proteins were resolved in 10% 
poly- acrylamide (29:1) gels containing 2mg/ml gelatin (Sigma).  Gels were washed 3x 30min in 
2.5% Triton-X solution,  washed in water,  then left in the  incubation  buffer (50mM  Tris  HCl,  
0.15M NaCl, 10mM CaCl2, pH 8) for 24-48h. Gels were stained with Coomassie Brilliant Blue G 
(0.05%), de-stained in 8% AcOH and 4% MetOH and im- aged using GelDoc EZ system (Biorad).  
The protein bands staining intensity was used as a loading control [Supplementary Figure S2] and 
densitometric analyses were performed using the integrated density measurement function of the 
ImageJ software (Schindelin et al., 2012). Ex-vivo, in situ zymography was performed on 10µm 
cryosections of TA muscles. Muscle sections adhered to glass slides were rehydrated in IGZ 
incubation buffer (as above), DQTM Gelatin (0.2mg/ml) was added and sections were left overnight 
at 37◦C and images were captured using LSM710 confocal (Zeiss). Cleavage site prediction was 
performed using CleavPredict (Sandford Burnham). 
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Western Blotting 
Proteins were extracted from adherent cells by  scraping in  100  µl ice-cold extraction buffer 
containing 1 x LysisM (Roche, 04719956001), 1x cOmplete ULTRA Mini EDTA-free protease 
inhibitor  cocktail  tablet  (Roche,  05892791001),  1 x PhosSTOP phosphatase inhibitor cocktail 
tablet (Roche, 04906845001), 2 mM sodium orthovana- date  (Sigma,  S6508).  Cells were 
disrupted by passing 10 times through a 25 g needle followed by centrifugation for 30 s at 
800 g.  Total proteins from frozen tissues were extracted in ice-cold extraction buffer (as above) 
using 50 passes in a glass Teflon homogenizer (Fisher Scientific, 11592543). Samples were 
centrifuged (800g for 3 min at 4°C) to remove debris and concentrations determined using the 
Bicinchoninic acid assay kit (Sigma, B9643). Twenty to 40 μg protein was mixed with Laemmli 
buffer at 1:1 v/v ratio with 2.5% v/v β-mercaptoethanol, heated for 5 min at 95°C, then chilled on 
ice prior to gel loading. Samples were separated on Any-Kd Mini-protean TGX ready gels (Bio-
Rad, 456–9034) and electro-blotted onto Hybond-P membranes (GE Healthcare, RPN303F). Blots 
were blocked in 5% w/v non-fat milk powder in 1x Tris buffered saline (TBST; 50 Mm Tris, 150 mM 
NaCl, 0.01% v/v Tween-20, Sigma T1503, S7653 and P1379, respectively), for 1 h prior to probing 
with primary antibody diluted in the same blocking buffer (overnight at 4°C or 2 h at room 
temperature), then washed (3 times) with 1 x TBST for 10 min and incubated with the appropriate 
horseradish peroxidase-conjugated secondary antibody; anti-mouse 1:10:000 (Sigma, A4416), 
anti-rabbit 1:5000 (Sigma, A6154) overnight at 4°C or 1 h at room temperature. Specific protein 
bands were visualized using Luminata Classico or Forte chemiluminescent substrates (Merck 
Millipore, WBLUC0500 and WBLUF0500, respectively), images were obtained using a ChemiDoc 
MP system (Bio-Rad, Hertfordshire, UK). Densitometric analyses were performed using the 
integrated density measurement function of ImageJ software. All experiments were repeated at 
least 3 times in triplicate throughout. 
Large pore and cell death assays 
For dye uptake assays, cells were incubated in the Large Pore (LP) buffer (145mM NaCl, 5mM 
KCl, 1mM MgCl2 and 10mM Na-HEPES) containing 5µM ethidium bromide (EtBr). Following 
addition of agonists, EtBr uptake was analysed under LSM510 confocal microscope (Zeiss) with 
heated stage and a dipping objective, or using POLARstar Optima plate reader (BMG Labtech). 
Cell death was assessed by LDH release, measured using in vitro toxicology assay kit (Sigma) as 
described in Young et al. (2015).   
Intracellular Ca2+ measurements 
Muscle cells were cultured on glass coverslips in a 6-well plate (500,000 cells/well) for 48 h under 
conditions described above. Cells (70–80% confluent) were loaded with Fura-2 AM (Molecular 
Probes, Oregon) in culture medium for 15 min at 37◦C in a 95% O2, 5% CO2 atmosphere. After 
two brief washes in the assay buffer (5mM KCl, 1mM MgCl2, 0.5mM Na2HPO4, 25mM HEPES, 
130mM NaCl, 1mM pyruvate, 5mM D-glucose, and 2mM CaCl2; pH 7.4), the coverslips were 
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mounted in a cuvette and maintained in the assay buffer at room temperature in RF5301PC 
spectrofluorimeter (Shimadzu). Fluorescence was recorded at 510nm with excitation at 
340/380nm. At the end of each experiment the Fura-2 fluorescence was calibrated by addition of 
13µM ionomycin to determine maximal fluorescence. Each experiment was repeated at least five 
times. 
Data analysis and statistics 
Results are reported as means +/- standard deviation where n refers to number of independent 
experiments (Browne et al., 2013; Pippel et al., 2017; Young et al., 2015; Rigato et al., 2012). For 
statistical analysis, a one-way analysis of variance (ANOVA) was performed with the post- hoc 
Tukey‘s test (Microcal Origin 7.0). Differences were considered statistically significant at p<0.05. 
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FIGURE LEGENDS 
Figure 1:  MMP-2 activity is constitutively upregulated in dystrophic myoblasts and is released 
following P2X7 activation. (A) IGZ showed MMP-2 activity being significantly upregulated in 
dystrophic cells, whilst MMP-9 activity being downregulated. (B) Western blot showed MMP-2 and 
9 protein levels not corresponding with their activity. (C) IGZ revealed that in dystrophic but not 
WT myoblasts ATP (3mM) produced a rapid and significant release of active MMP-2. (D) 
Quantification of MMP-2 activity in IGZ from pellets and supernatants (SuperN) of 
dystrophic myoblasts. Immunoblot analysis using anti-MMP-2 antibody confirmed the 
decrease of MMP-2 in mdx cell pellets. (E) MMP-2 protein was released from dystrophic 
myoblasts following BzATP (0.5 mM) treatment; this effect was blocked by the P2X7 LP 
antagonist A438079 (10M). (F) Quantification of MMP-2 protein levels in cell pellets following 
BzATP treatment +/- A438079. (G) MMP-2 protein was concomitantly detectable in concentrated 
cell culture supernatants from treated cells. ( H )  T i m e - d e p e n d e n t  r e l a t i o n s h i p  
b e t w e e n  M M P - 2  p r o t e i n  a n d  L D H  l e v e l s  i n  m d x  m y o b l a s t  s u p e r n a t a n t s  
f o l l o w i n g  B z A T P  t r e a t m e n t . ( I )  P2X7 involvement in MMP-2 release was confirmed in 
IGZ using pellets and supernatants from myoblasts treated with the selective P2X7 agonist, BzATP 
+/- 10 min pre-incubation with 10M P2X7 antagonist A438079.  (J) Quantification of MMP-2 
activity in mdx myoblast supernatants following BzATP treatment over 60mins. Where three 
replicates are shown, these represent three independent biological samples. Actin and total 
protein (Coomassie staining) band intensities are shown as loading controls. Molecular weight 
markers in IGZ are shown as a guide only. *P<0.05, ***P<0.001. 
 
Figure 2:  P2X7-dependent cleavage of ce l l  sur face  recepto rs  following MMP-2 release.  
(A) In serum-free medium dystrophic myoblasts exposed for 30 min to BzATP displayed cleavage 
of β-dystroglycan revealing a strong 30 kDa band. (B) Quantification of native and cleaved-
dystroglycan protein levels in mdx myoblasts following BzATP treatment over 60min (C). P2X7-
dependent cleavage of CD44 in BzATP-treated mdx myoblasts released a ~25 kDa band. (D) 
Quantification of native and cleaved CD44 protein levels following BzATP treatment in mdx 
myoblasts. This P2X7-dependent degradation was absent in WT myoblasts, which lack P2X7 
expression (A and C, upper panels). TA = tibialis anterior. *P<0.05, ***P<0.001. 
 
Figure 3: MMP-2 activity suppresses P2X7 functions. (A, upper panel) Exposure of mdx 
myoblasts to ATP in the presence of FBS (with high levels of MMP activity) produced no 
detectable change in MMP-2 activity in cell pellets irrespective of the ATP concentration used 
(0.1-1 mM) and did not induce any P2X7-dependent EtBr uptake (B, bottom panel). In the 
absence of serum, MMP-2 activity was released from cells (activity decreased in cell pellets)  
following stimulation with increasing ATP concentrations (A, lower panel). (B) Unlike bovine 
(FBS) and horse (DHS) sera containing high MMP activity, the serum-replacement medium 
(KSR) is MMP-free and in KSR but not in FBS or DHS, the ethidium bromide (EtBr) fluorescence 
was observed. (C) Quantification of EtBr uptake in mdx myoblasts treated with ATP in 
different sera concentrations. (D) Specific MMP-2 inhibitor caused a dose-dependent reduction 
of MMP-2 activity, which (E) correlated with enhanced EtBr uptake and confirmed the role of 
MMP-2 in this response. EtBr uptake was also reversed by the addition of active recombinant 
mouse MMP-2 or MMP-2-containing serum (FBS, 5%). (F) Calcium influx via P2X7 channels was 
also inhibited in the presence of recombinant or serum-born MMP-2 activity. (G) Diagrammatic 
representation summarizing the proposed temporal relationship between P2X7 receptor function 
and MMP-2 activity. Scale bar = 10m. *P<0.05, ***P<0.001. 
 
Figure 4: P2X7-dependent MMP-2 release occurs in macrophages and P2X7-transfected HEK 
cells. Raw264 mouse macrophages showed a rapid release of MMP-2 following BzATP 
stimulation (A, top panels) and this response was completely blocked when cells were treated 
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with BzATP in the presence of 10% FBS (A, lower panels).  (B) Quantification of MMP-2 
activity in pellets of BzATP-treated Raw264 cells +/- FBS (10%). (C) The same effect 
was observed in wild type (C57BL10) primary peritoneal macrophages but not in the P2X7 
ablated (mdx/P2X7-/-) macrophages. (D) Quantification of MMP-2 activity in pellets and 
supernatants (SuperN) from peritoneal macrophages following BzATP stimulation. 
Activation of P2X7 and the MMP release in macrophages were associated with β-dystroglycan 
cleavage (E & F) and the P2X7-evoked EtBr uptake (G) was augmented by MMP-2 inhibitor but 
reduced by the exposure to active recombinant MMP2. (H) IGZ showing MMP-2 activity in treated 
cell supernatants from HEK cells transfected with P2X7 demonstrating up-regulated MMP-2 activity 
and P2X7-dependent MMP-2 release. No detectable MMP-9 activity in these cells confirmed the MMP-2 
specific effect. *P<0.05, ***P<0.001. 
 
Figure 5:  P2X7 is a proteolytic target for MMP-2.  (A, upper panel) Stimulation with BzATP, 
shown to trigger active MMP-2 release, was associated with reductions in the 80 kDa P2X7 band 
in Western blots of dystrophic myoblasts (3 biological replicates shown). (A, lower panel) 
Reduction of the 80 kDa P2X7 band was concomitant with the appearance of an approx. 35 kDa 
band detected with the antibody targeting the C-terminus of P2X7. This 35 kDa band was absent 
when samples were treated with BzATP in the presence of the MMP-2 Inhibitor I. (B) 
Quantification of the cleavage product vs. the native protein band estimated it to be approx. 40% 
and there was no cleaved product if the MMP-2 inhibitor was used. (C) Time course experiment 
showing cleavage to occur 5-15 mins following P2X7 activation. (D) Quantification of P2X7 cleavage 
product level over time. (E) The 35 kDa cleavage product was identified in samples from peritoneal 
macrophages and P2X7-transfected HEK cells (HEKP2X7) and found following sample incubation 
(30 min, 37oC) with activated recombinant MMP-2 (recMMP-2 active). It was completely absent in 
samples treated with an inactive enzyme (recMMP-2, pro). (F) Quantification of P2X7 native 
protein and cleaved band levels in cell samples following incubation with recombinant MMP-
2. (G) Cleavage site prediction (CleavPredict) identified several potential MMP-2 sites in the 
mouse P2X7 sequence (Uniprot ID, Q9Z1MO) and those corresponding to C-term fragments of 
approx. 35 kDa are shown. PWM = position weight matrix score. ***P<0.001. 
 
Figure 6: MMP-2 release prevents LP formation and death despite high P2X7 expression in 
human prostate cancer cells. (A) Western blot of significantly higher P2X7 expression in the 
LNCaP cancer cell line than in dystrophic myoblasts, shown here as a positive control (mdx mbs.) 
P2X7 expression in LNCaP lysates was not altered following BzATP treatment. (B) The LNCaP cells 
displayed low levels of EtBr uptake following P2X7 stimulation with ATP but EtBr uptake was 
significantly elevated in the presence of MMP-2 inhibitor. Addition of recMMP-2 ablated this effect 
as did the presence of 10% serum (DHS). Graph shows the signal as % of the EtBr uptake 
triggered by digitonin-induced membrane permeabilisation. (C) In-gel zymography in LNCaP cell 
lysates and culture supernatants following 30 min treatment with BzATP showed a significant 
constitutive release of MMP-2 and 9, elevated further by P2X7 stimulation. (D) LDH release 
assay used as a measure of cell death (Chan et al., 2013). Following 60 min stimulation with 
3mM ATP there was very low cell death, which was completely suppressed by the serum (10% 
DHS) but very significantly enhanced in cells treated with the MMP-2 inhibitor. *P<0.05, 
***P<0.001. 
 
Figure 7:  P2X7 ablation reduces MMP activity in dystrophic muscles in vivo. (A) In situ 
zymography in cryosections of 8 week old mdx tibialis anterior muscle using a fluorophore-
quenched gelatin substrate demonstrated a significant upregulation of MMP activity (green) in 
infiltrating immune cell populations (F4/80 macrophage marker shown in red) and also in and around 
central nuclei of regenerating myofibers (inset). This activity was significantly reduced in mdx/P2X7-
/- muscles and in the presence EDTA (right panel). (B) Quantification of ISZ activity in TA muscle 
sections. (C) Immunoblotting showing that MMP-2 protein levels were actually reduced in mdx 
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compared to WT muscles whilst there was no significant difference between mdx and mdx/P2X7-/- 
samples - a result in clear contrast to the activity levels of these enzymes. *P<0.05. 
 
Figure 8:  Mechanism of P2X7-dependent pore formation, MMP-2 activation and its functional 
consequences. (Left panel) β-dystroglycan binds α-dystroglycan which interacts with extracellular 
matrix proteins (e.g.) laminin. CD44 binds ERM proteins, which in turn bind actin, forming a link 
between membrane and cytoskeleton. P2X7 C-terminus associates with Hsp90, which binds to 
and stabilizes MMP-2. (Right panel) Following sustained P2X7 stimulation the ―large pore‖ 
response is activated; MMP-2 is released, facilitating β-dystroglycan degradation disrupting links 
with both intra and extracellular scaffolds. The extracellular CD44 cleavage product may bind to 
and augments P2X7 function (Michaluk et al., 2007) while MMP-2 activity halts all P2X7 functions 
through a direct receptor cleavage. 
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